FDA's Gastrointestinal Drugs Advisory Cmte. will discuss company's supplemental NDA for Cytotec (misoprostol) for prevention of NSAID-induced peptic ulceration at panel's Sept. 15-16 meeting. While Searle's NDA for short-term treatment of duodenal ulcer, pending since 1984, appears to be hung up, the concomitant use with NSAID's has a 1-A rating at FDA and looks to be moving toward approval. Panel will also review Pharmacia's Dipentum (olsalazine) for prolongation of remission between acute attacks of ulcerative colitis, treatment of mild ulcerative colitis, and as adjunctive therapy for moderate to severe ulcerative colitis.
You may also be interested in...
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.